Detalhe da pesquisa
1.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139273
2.
High tumour-infiltrating lymphocytes correlate with distinct gene expression profile and favourable survival in single hormone receptor-positive breast cancer.
Contemp Oncol (Pozn)
; 28(1): 75-83, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38800535
3.
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast Cancer Res Treat
; 188(3): 631-640, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34148205
4.
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Br J Cancer
; 120(2): 172-182, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568294
5.
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
Br J Cancer
; 119(6): 663-669, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30197417
6.
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Lancet Oncol
; 18(7): 917-928, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28592386
7.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 18(5): 611-622, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28359784
8.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet
; 383(9911): 31-39, 2014 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24094768
9.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24933332
10.
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Breast Cancer Res Treat
; 143(3): 493-505, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24402830
11.
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Clin Cancer Res
; 29(22): 4564-4574, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363992
12.
High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series.
Pathology
; 54(3): 269-278, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074178
13.
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Clin Lung Cancer
; 23(7): e415-e427, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35729005
14.
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.
Cancers (Basel)
; 14(5)2022 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35267477
15.
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Onkologie
; 34(5): 233-8, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21577028
16.
microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
Diagnostics (Basel)
; 10(9)2020 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32825530
17.
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
J Immunother Cancer
; 8(1)2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32503946
18.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Lung Cancer
; 112: 126-133, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191585
19.
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Lung Cancer
; 93: 95-103, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26898621
20.
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
Breast
; 24(6): 769-73, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384789